Finance / ICAD (Icad Inc.)

  Recs: 1 Press release Allon Therapeutics Reviews Product Development at BIO-Europe 2008 Monday November 17, 9:00 am ET VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 17, 2008) - Allon Therapeutics Inc. (TSX:NPC - News), will review progress of its clinical-stage Alzheimer's disease and preclinical-stage peripheral neuropathy programs November 18 at BIO-Europe 2008 in ...

  Recs: 0 CABG Allon Therapeutics Releases Phase II MCI-CABG Results Thursday August 28, 4:21 pm ET VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 28, 2008) - Allon Therapeutics Inc. (TSX:NPC - News) announced today that in a Phase IIa clinical trial evaluating the potential of its drug AL-208 to prevent or reduce mild cognitive impairment (MCI) in patients who undergo ...

  Recs: 96 Reuters & Hedge Funds - Just sent this to a senior officer at Elan Hi X,   In view of the Reuters News Release that went out at 5pm on July 29 th whilst Elan was presenting at ICAD (which started the snowball that became an avalanche), I thought that you should see these news report on Reuters “aiding hedge funds”. I wonder how Ms. Julie ...

  Recs: 0 Re: 6,372,400 The price that day ended at 1.07 for that day. My wag is this transaction was done by the underwriters of the 19 million share stock offering completed in July. The 6 million share transaction was for a couple of cents higher than the 1.05 paid in the offering so someone could have made a very modest profit if they immediately sold. Not sure if they ...

  Recs: 6 Bap mentioned in Neurotech Insights Alzheimer's Disease and Emerging Treatments Analyzed in Neurotech Insights SAN FRANCISCO, Aug 20, 2008 /PRNewswire via COMTEX/ -- Emerging therapeutic strategies for Alzheimer's disease is the focus of the most recent edition of Neurotech Insights, the leading monthly industry newsletter covering drugs, devices and diagnostics ...